How long does Bravecto remain effective for dogs against ticks? - briefly
A single oral dose safeguards a dog against ticks for up to 12 weeks. Clinical studies have confirmed this duration of efficacy across the most common tick species.
How long does Bravecto remain effective for dogs against ticks? - in detail
Bravecto is a systemic ectoparasiticide formulated as a chewable tablet containing the active ingredient fluralaner. After oral administration, the compound is absorbed rapidly, reaches peak plasma concentrations within 2–4 hours, and distributes throughout the body’s tissues, including skin and hair follicles where ticks attach. The drug’s half‑life in canine plasma ranges from 12 to 15 days, enabling sustained therapeutic levels for an extended period.
Efficacy against ticks has been demonstrated for a full twelve‑week interval following a single dose. Clinical trials involving common species such as Ixodes ricinus, Dermacentor variabilis, Rhipicephalus sanguineus, and Amblyomma americanum show ≥ 95 % kill rate within 48 hours of attachment throughout the entire dosing period. The protective window remains consistent regardless of the dog’s weight class, provided the correct dose (based on body mass) is administered.
Factors that may influence the duration of protection include:
- Health status: Severe hepatic or renal disease can alter drug metabolism, potentially shortening effective plasma concentrations.
- Concurrent medications: Strong inducers of cytochrome P450 enzymes may increase clearance, whereas inhibitors could prolong exposure.
- Age: Puppies younger than eight weeks are not approved for treatment; older dogs maintain the standard efficacy profile.
Dosage recommendations specify one tablet per dog, with the amount calibrated to weight ranges (e.g., 2 mg/kg). The tablet can be given with or without food, and no repeat dosing is required until the twelve‑week interval lapses. If a dog is exposed to a heavy tick burden shortly before the next dose, an additional treatment may be considered, but only under veterinary guidance to avoid overdosing.
Safety data indicate a low incidence of adverse events. Most reported reactions are mild and transient, such as gastrointestinal upset or temporary lethargy. No cumulative toxicity has been observed with repeated administrations at the approved interval.
In summary, a single oral administration of Bravecto provides continuous tick control for approximately three months, with consistent efficacy across major tick species, provided the product is used according to label instructions and the animal’s health status does not contraindicate treatment.